Abstract
ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
Clinical lymphoma, myeloma and leukemia, Vol.23(Suppl. 1), pp.S442-S443
09/2023
DOI: 10.1016/S2152-2650(23)01338-1
Abstract
The treatment landscape for LBCL has evolved dramatically in recent years with the introduction of chimeric antigen receptor (CAR) T-cell therapy and novel agents. However, chemo-immunotherapy (CIT) remains a standard of care (SOC) for patients with r/r disease after ≥2 previous lines of therapy. This study characterized real-world clinical outcomes of LBCL patients who received CIT in the third or later line (3L+) of therapy.
Design
A multi-site retrospective observational study was conducted using data for patients in the Lymphoma Epidemiology of Outcomes (LEO) Consortium of Real-World Evidence (CReWE) cohort (1/1/2015–2/15/2023) who were treated with CIT in 3L+ at one of eight academic centers. CIT regimens included salvage/ palliative chemotherapy, lenalidomide, rituximab, or obinutuzumab, used alone or in combination.
Outcomes
The effectiveness of CIT treatment was evaluated based on real-world overall response rate (rwORR), complete response (rwCR), duration of response (rwDOR), duration of CR (rwDOCR), progression-free survival (rwPFS), and overall survival (OS). Outcomes were also characterized in two subgroups of patients: those with prior CAR T-cell therapy and those with diffuse LBCL (DLBCL).
Results
There were 176 LBCL patients in the 3L+ CIT-treated cohort. The median (range) age was 61.2 (22.4-88.2) years; 75% were male, 85% had an ECOG performance status score of 0/1, 73% had de novo LBCL, 10% had transformed LBCL, 37% had an IPI score ≥3, 73% had Ann Arbor stage III/IV. Median number of previous lines of anti-lymphoma therapies was 2 (range 2–7); 92% of patients were refractory to their most recent anti-CD20 therapy, 71% had primary refractory disease, 18% had prior autologous stem cell transplantation, and 16% had prior CAR T-cell therapy. Outcomes were as follows: ORR, 27%; CR, 12%; and median DOR DOCR, PFS, and OS, 3.1, 10.9, 1.8, and 5.2 months, respectively. Outcomes were similar for the DLBCL subgroup, and worse for the prior CAR T-cell subgroup.
Conclusions
Patients with r/r LBCL treated with CIT in 3L+ have poor outcomes, underscoring the need for novel, effective, and well-tolerated therapies. This cohort provides a reference for trials evaluating 3L+ treatment in r/r LBCL.
Details
- Title: Subtitle
- ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
- Creators
- Loretta J. NastoupilClark AndersenAmy AyersYucai WangThomas M. HabermannDai ChiharaBrad S. KahlBrian K. LinkSabarish AyyappanJonathon B. CohenPeter MartinIzidore S. LossosCarla CasuloRuitao LinZiyi LiMelissa A. LarsonMatthew J. MaurerLynn HuynhChi GaoRamya RamasubramanianMei Sheng DuhAlex MutebiTongsheng WangMonika JunAnthony WangRajesh KamalakarAnupama KalsekarJames R. CerhanChristopher R. Flowers
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.23(Suppl. 1), pp.S442-S443
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S2152-2650(23)01338-1
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 09/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine; Epidemiology
- Record Identifier
- 9984461351502771
Metrics
2 Record Views